Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X CleanTech (CTEC) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X CleanTechTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Global X CleanTech vs Cassava Sciences Inc — how do they compare? Global X CleanTech trades at $56.49, while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Global X CleanTech is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

CTECFLNA
Sector
Sector/ThematicHealth
52-Week High
$78.11$4.64
52-Week Low
$39.45$1.09
Market Cap
$52.66M
Enterprise Value
-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X CleanTech

No Aura AI signal available yet.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

About Global X CleanTech

CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.

Read more on CTEC

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA